MRI Features Can Predict 1p/19q Status in Intracranial Gliomas

References

1. 1.↵
   2. Louis DN,
   3. Perry A,
   4. Reifenberger G, et al

   . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016;131:803–20 doi:10.1007/s00401-016-1545-1 pmid:27157931

   CrossRefPubMed
2. 2.↵
   2. Lasocki A,
   3. Tsui A,
   4. Gaillard F, et al

   . Reliability of noncontrast-enhancing tumor as a biomarker of IDH1 mutation status in glioblastoma. J Clin Neurosci 2017;39:170–75 doi:10.1016/j.jocn.2017.01.007 pmid:28214089

   CrossRefPubMed
3. 3.↵
   2. Patel SH,
   3. Poisson LM,
   4. Brat DJ, et al

   . T2-FLAIR mismatch, an imaging biomarker for IDH and 1p/19q status in lower-grade gliomas: a TCGA/TCIA project. Clin Cancer Res 2017;23:6078–85 doi:10.1158/1078-0432.CCR-17-0560 pmid:28751449

   Abstract/FREE Full Text
4. 4.↵
   2. Tay K,
   3. Tsui A,
   4. Phal P, et al

   . MR imaging characteristics of protoplasmic astrocytomas. Neuroradiology 2011;53:405–11 doi:10.1007/s00234-010-0741-2 pmid:20644924

   CrossRefPubMed
5. 5.↵
   2. Saito T,
   3. Muragaki Y,
   4. Maruyama T, et al

   . Calcification on CT is a simple and valuable preoperative indicator of 1p/19q loss of heterozygosity in supratentorial brain tumors that are suspected grade II and III gliomas. Brain Tumor Pathol 2016;33:175–82 doi:10.1007/s10014-016-0249-5 pmid:26849373

   CrossRefPubMed
6. 6.↵
   2. Johnson DR,
   3. Diehn FE,
   4. Giannini C, et al

   . Genetically defined oligodendroglioma is characterized by indistinct tumor borders at MRI. AJNR Am J Neuroradiol 2017;38:678–84 doi:10.3174/ajnr.A5070 pmid:28126746

   Abstract/FREE Full Text
7. 7.↵
   2. Smits M

   . Imaging of oligodendroglioma. Br J Radiol 2016;89:20150857 doi:10.1259/bjr.20150857 pmid:26849038

   CrossRefPubMed
8. 8.↵
   2. Osborne AG

   . Osborne's Brain: Imaging, Pathology and Anatomy. Salt Lake City: Amirsys; 2013:496
9. 9.↵
   2. Law M,
   3. Brodsky JE,
   4. Babb J, et al

   . High cerebral blood volume in human gliomas predicts deletion of chromosome 1p: preliminary results of molecular studies in gliomas with elevated perfusion. J Magn Reson Imaging 2007;25:1113–19 doi:10.1002/jmri.20920 pmid:17520715

   CrossRefPubMed
10. 10.↵
    2. Law M,
    3. Yang S,
    4. Wang H, et al

    . Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003;24:1989–98 pmid:14625221

    Abstract/FREE Full Text
11. 11.↵
    2. Lasocki A,
    3. Tsui A,
    4. Tacey MA, et al

    . MRI grading versus histology: predicting survival of World Health Organization grade II–IV astrocytomas. AJNR Am J Neuroradiol 2015;36:77–83 doi:10.3174/ajnr.A4077 pmid:25104288

    Abstract/FREE Full Text
12. 12.↵
    2. Gonzales M,
    3. Dale S,
    4. Susman M, et al

    . Quantitation of chromosome 1p and 19q deletions in glial tumours by interphase FISH on formalin-fixed paraffin-embedded tissue. J Clin Neurosci 2006;13:96–101 doi:10.1016/j.jocn.2005.06.004 pmid:16410204

    CrossRefPubMed
13. 13.↵
    VASARI Research Project. https://wiki.cancerimagingarchive.net/display/Public/VASARI+Research+Project. . Updated March 25, 2015Accessed August 20, 2015.
14. 14.↵
    2. Louis DN,
    3. Ohgaki H,
    4. Wiestler OD, et al

    . World Health Organization Histological Classification of Tumours of the Central Nervous System. Lyon: International Agency for Research on Cancer; 2016
15. 15.↵
    2. Brat DJ,
    3. Verhaak RG,
    4. Aldape KD, et al

    ; Cancer Genome Atlas Research Network. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 2015;372:2481–98 doi:10.1056/NEJMoa1402121 pmid:26061751

    CrossRefPubMed
16. 16.↵
    2. Clark KH,
    3. Villano JL,
    4. Nikiforova MN, et al

    . 1p/19q testing has no significance in the workup of glioblastomas. Neuropathol Appl Neurobiol 2013;39:706–17 doi:10.1111/nan.12031 pmid:23363074

    CrossRefPubMed
17. 17.↵
    2. Ito M,
    3. Wakabayashi T,
    4. Natsume A, et al

    . Genetically heterogeneous glioblastoma recurring with disappearance of 1p/19q losses: case report. Neurosurgery 2007;61:E168–69; discussion E169 doi:10.1227/01.neu.0000279739.53425.5c pmid:17621007

    CrossRefPubMed
18. 18.↵
    2. Huse JT,
    3. Diamond EL,
    4. Wang L, et al

    . Mixed glioma with molecular features of composite oligodendroglioma and astrocytoma: a true “oligoastrocytoma”? Acta Neuropathol 2015;129:151–53 doi:10.1007/s00401-014-1359-y pmid:25359109

    CrossRefPubMed
19. 19.↵
    2. Qu M,
    3. Olofsson T,
    4. Sigurdardottir S, et al

    . Genetically distinct astrocytic and oligodendroglial components in oligoastrocytomas. Acta Neuropathol 2007;113:129–36 doi:10.1007/s00401-006-0142-0 pmid:17031656

    CrossRefPubMedWeb of Science
20. 20.↵
    2. Lasocki A,
    3. Gaillard F,
    4. Tacey M, et al

    . Incidence and prognostic significance of non-enhancing cortical signal abnormality in glioblastoma. J Med Imaging Radiat Oncol 2016;60:66–73 doi:10.1111/1754-9485.12421 pmid:26597591

    CrossRefPubMed
21. 21.↵
    2. Tang YM,
    3. Ngai S,
    4. Stuckey S

    . The solitary enhancing cerebral lesion: can FLAIR aid the differentiation between glioma and metastasis? AJNR Am J Neuroradiol 2006;27:609–11 pmid:16552003

    Abstract/FREE Full Text
22. 22.↵
    2. Louis DN,
    3. Ohgaki H,
    4. Wiestler OD, et al

    . World Health Organization Histological Classification of Tumours of the Central Nervous System. Lyon: International Agency for Research on Cancer; 2007